Drägerwerk stock carries a stronger 2026 margin outlook

Published on 10/07/2026 at 13:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Drägerwerk stock was at EUR 114.80 on October 7, 2026, while first-half EBIT reached EUR 64 million. Management guides to a 6 to 8 percent EBIT margin, with Q3 results due October 29.

Moderne Intensivstation mit Beatmungsgerät und Patientenmonitoring in klinischer Umgebung — Drägerwerk AG & Co. KGaA zeigt moderne Intensivstation mit Beatmungsgeräten und Patientenmonitoring DE0005550636, Illustration mit AI erstellt.

Drägerwerk stock (ISIN DE0005550636) was trading at EUR 114.80 on Xetra on October 7, 2026 at 1:18 p.m. CEST, down 0.86 percent from the previous close. The medical and safety technology group entered the second half of 2026 with first-half EBIT of EUR 64 million and an EBIT margin of 4.0 percent, according to the July 30 earnings call transcript published by Yahoo Finance. The operating improvement is now the central valuation issue.

EBIT more than tripled

According to Yahoo Finance, Drägerwerk increased first-half EBIT from EUR 20 million in the prior-year period to EUR 64 million in 2026. The corresponding EBIT margin moved from 1.3 percent to 4.0 percent, while net sales increased 7.7 percent on a currency-adjusted basis.

Order intake reached EUR 1.75 billion in the first six months, up 1.8 percent from the prior-year period. The split between divisions matters: safety technology order intake rose 9.5 percent, while medical technology order intake fell 3.7 percent because of a comparison effect linked to a large prior-year hospital infrastructure order in Mexico.

Guidance reaches 8 percent

Management now expects a 2026 EBIT margin of 6 percent to 8 percent, compared with the earlier lower end of 5.5 percent, as reported in the Yahoo Finance transcript. The company also expects currency-adjusted net sales growth of 2 percent to 6 percent.

Customs refunds are an important counter-factor. Drägerwerk said EUR 14.2 million of additional refunds received after the half-year balance sheet date will be recognized in third-quarter earnings, making the margin comparison less dependent on recurring operating gains.

Consensus trails the Xetra quote

The analyst picture is constructive but more cautious than the latest quote. A Marketscreener consensus lists an Outperform rating from five analysts and an average target of EUR 109.00, EUR 5.80 below the EUR 114.80 Xetra price. Finanztrends reported on September 8, 2026 that MWB Research had raised its target from EUR 114.00 to EUR 130.00, a separate view from the broader consensus.

The next scheduled checkpoints are October 29, 2026 for the third-quarter earnings release and November 18, 2026 for the capital markets day in Lübeck, according to Marketscreener and the earnings call transcript.

Stock stays below the yearly high

At EUR 114.80 on Xetra on October 7, 2026, Drägerwerk stock stood 8.45 percent below its 52-week high of EUR 125.40 and above its 52-week low of EUR 64.50. The EUR 2.2 billion market capitalization places the margin upgrade beside a share price that has already moved close to its annual peak.